SRR8942974
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- E2F_TARGETS+0.370
- MYC_TARGETS_V2+0.370
- ADIPOGENESIS+0.350
- MYC_TARGETS_V1+0.330
- PEROXISOME+0.330
- PROTEIN_SECRETION+0.310
- FATTY_ACID_METABOLISM+0.270
- DNA_REPAIR+0.250
- CHOLESTEROL_HOMEOSTASIS+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- INFLAMMATORY_RESPONSE-0.400
- COAGULATION-0.350
- KRAS_SIGNALING_UP-0.350
- ANGIOGENESIS-0.340
- KRAS_SIGNALING_DN-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168570 | — | — | 0.905 |
| 2 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.904 |
| 3 | bbeadeec-bb57-4762-8828-3bd1696748fb | — | — | 0.903 |
| 4 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.897 |
| 5 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.890 |
| 6 | TCGA-4Z-AA7S-01A-11R-A39I-07 | — | — | 0.890 |
| 7 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.889 |
| 8 | DRR168601 | — | — | 0.889 |
| 9 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.888 |
| 10 | R414 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |